Healthcare — ThinkEnix

Healthcare

DeepMind SynthID Bio — Watermarks AI protein sequences without changing function

Google DeepMind announced SynthID Bio, a family of watermarking methods that embed an imperceptible digital signature directly into AI-generated protein sequences without affecting biological function—a claimed world first. The watermark acts as a digital ID so DNA labs can verify synthetic proteins, keep sequence databases accurate, and confirm designs came from AI systems with built-in safeguards. Tools are being released openly for research use so labs can authenticate origin without slowing scientific work. It matters because it gives biosecurity a practical, non-disruptive way to trace AI-designed biology as protein generation scales.

Healthcare

Claude finds novel CRISPR-like ART enzyme system in phages

Anthropic launched a life sciences lab where Claude agents, given a high-level prompt, searched DNA databases for reverse transcriptases. After 21 hours, ~950 agents, and 210 million tokens, one agent found repeating non-coding DNA next to an unusual jumbo-phage RT plus an unknown accessory protein—a combination previously seen mainly in programmable DNA-cutting/copying systems. Lab follow-up named the uncharacterized system array-associated reverse transcriptases (ART); function is still unknown. Early sharing and a preprint matter because such molecular machines have historically become gene-editing and diagnostic tools.

The Feed

Signals about how SI and robotics are reshaping our world.

Healthcare1mo ago

Novo Nordisk partners with Anthropic to speed drug R&D with Claude

Novo Nordisk has partnered with Anthropic to apply Claude models and Claude Science in drug discovery and development workflows, targeting scientific problems where the combination can have the greatest impact. The Danish maker of Wegovy will also use Anthropic frontier models to strengthen AI-driven software development; it already uses Claude to automate trial report generation and cut patient-documentation timelines from months to minutes. The move puts a major pharma pipeline on frontier models to compress R&D and documentation cycles.

reuters.com

Healthcare1mo ago

Google AI — AlphaGenome maps 9B variants; WeatherNext 3 live

Google said its AI now supports more than 300 languages spoken by 7 billion people (86% of the global population) and released AlphaGenome Atlas, mapping all 9 billion possible single-letter human genetic changes and opening it to researchers. WeatherNext 3, its latest global weather model, is already in products with 50% more accurate precipitation forecasts a day or more ahead; a Planetary Prediction Engine has been used on the DRC Ebola outbreak and 21 CDC health indicators. AlphaFold has predicted 200 million protein structures and is used by 4 million researchers in 190 countries; a UK NHS breast-cancer study found AI detected 25% of interval cancers missed in 175,000 mammograms, and TB and diabetic-retinopathy tools have screened tens of thousands to over a million people. The work puts large-scale scientific models into disease detection, disaster forecasting, and open research today.

blog.google

Healthcare1mo ago

Novartis remibrutinib cuts MS relapse rates in dual Phase III trials

Novartis announced positive topline results from its Phase III REMODEL-1 and REMODEL-2 trials of remibrutinib, an oral BTK inhibitor, in relapsing multiple sclerosis. Across approximately 2,000 patients, remibrutinib demonstrated superiority over teriflunomide in reducing annualized relapse rates, cutting MRI lesions, and achieving clinically meaningful delays in disability progression. The drug showed no liver safety signal across a clinical program of more than 4,500 participants, and Novartis plans to submit for global regulatory approval. This positions remibrutinib as a potential high-efficacy oral alternative in a disease affecting nearly 3 million people worldwide.

novartis.com

Healthcare1mo ago

Moderna & Merck's mRNA cancer vaccine succeeds in Phase 3 trial

Moderna and Merck announced that their personalized mRNA cancer vaccine, Intismeran, succeeded in late-stage Phase 3 testing — the first therapeutic cancer vaccine to do so after over 100 years of failed attempts. In a trial of more than 1,000 melanoma patients, Intismeran reduced tumor recurrence and spread when combined with Merck's immunotherapy Keytruda. The vaccine uses an algorithm to analyze thousands of tumor mutations and encode 34 personalized neoantigens into a bespoke mRNA shot for each patient. Merck invested $450 million into the partnership since 2016, and Wall Street is already projecting billions in sales.

reuters.com

Healthcare3mo ago

FDA approves daily pill that cuts cholesterol beyond statin limits

The FDA has approved a new daily oral pill designed to lower cholesterol levels significantly beyond what statins — the current standard of care — can achieve. The approval is backed by clinical trial results demonstrating superior LDL reduction compared to existing treatments. Statins are among the most widely prescribed drugs in the world, making this a notable shift in cardiovascular treatment options. A pill-based alternative that outperforms statins could reshape prescribing guidelines and expand access to effective cholesterol management for millions of patients.

x.com

Healthcare3mo ago

RetinaMind — AI tool diagnoses autism and ADHD via retinal scans at 89% accuracy

Edward Kang, a 17-year-old high school senior from Bergen County Academies in New Jersey, developed RetinaMind, an AI tool that diagnoses autism spectrum disorder and ADHD by analyzing retinal images with 89% accuracy. The system uses ensemble learning — feeding retinal images to multiple CNN models and combining their predictions — to distinguish between the two disorders rather than simply detecting one. It won second place and $175,000 at the 2026 Regeneron Science Talent Search. With no existing physical biomarker tests for autism or ADHD, a non-invasive retinal imaging approach could enable earlier diagnosis and intervention for the millions of children affected by these conditions.

smithsonianmag.com

Healthcare3mo ago

Conception generates first early human eggs from stem cells

Conception has produced the first early-stage human eggs (oocytes) derived from induced pluripotent stem cells reprogrammed from a patient's blood cells, which were then guided to form miniature human ovaries called ovaroids. The process requires only a simple blood draw, bypassing the hormonal injections and surgeries currently required for IVF egg retrieval. Healthy mice have previously been born using this approach, and while significant safety and efficacy work remains before human clinical use, the milestone marks a major advance in in vitro gametogenesis (IVG). If validated, this technology could make fertility treatments far less invasive, extend the reproductive window for women, and serve as a research platform for menopause and aging.

x.com

Healthcare4mo ago

Midjourney Medical — 60-second whole-body Ultrasonic CT scanner announced

Midjourney, known for AI image generation, has announced Midjourney Medical: a full-body imaging device called Ultrasonic CT that uses sound waves and a water submersion ring embedded with ~500,000 grain-of-sand-sized sensors to produce a 3D body map in under 60 seconds. Founder David Holz calls it 'the first new whole-body medical imaging modality in 50 years,' targeting MRI-comparable resolution at nearly 100x the speed. The Gen 1 prototype currently takes ~20 minutes due to bandwidth and infrastructure bottlenecks, with roughly a dozen people scanned so far by a nine-person team. If realized at scale, this could make routine whole-body scanning as accessible and fast as a routine health check.

midjourney.com

Healthcare6mo ago

Single injection gene therapy reverses deafness in all 10 trial patients

A gene therapy trial in China successfully restored hearing in all 10 patients with OTOF gene mutations using a single injection of AAV virus carrying a working OTOF gene into the inner ear. Patients showed dramatic improvement from an average of 106 dB hearing loss to 52 dB, with some beginning to hear within weeks and a 7-year-old girl conversing with her mother after 4 months. The treatment worked across age groups from infants to adults, proving AAV delivery is safe and effective for genetic deafness. This represents the first root-cause treatment for hereditary hearing loss that could scale to other common deafness genes affecting millions globally.

x.com

Healthcare6mo ago

Meta TRIBE v2 — AI predicts brain responses to any sight or sound

Meta released TRIBE v2, a foundation model that predicts human brain responses to visual and auditory stimuli using 500+ hours of fMRI data from 700+ people across ~1,000 brain regions. The model achieves 2-3x performance improvements over previous methods and can make zero-shot predictions for new subjects, languages, and tasks without retraining. Meta open-sourced the model, code, and paper to advance neuroscience research and accelerate breakthroughs in neurological disease diagnosis and treatment.

x.com

Healthcare7mo ago

Tech entrepreneur uses ChatGPT to design world's first personalized mRNA cancer vaccine for dog

Sydney tech entrepreneur Paul Conyngham used ChatGPT to help sequence his dog Rosie's tumor DNA and design a personalized mRNA cancer vaccine, collaborating with UNSW RNA Institute director Páll Thordarson to create the world's first personalized cancer vaccine for dogs. The vaccine shrunk Rosie's mast cell tumors by 75% within a month of treatment, after traditional chemotherapy had failed. This represents a breakthrough application of AI-assisted personalized medicine extending from human healthcare into veterinary treatment.

theaustralian.com.au

Healthcare7mo ago

Stanford Screenomics — Open platform turns phones into health research tools

Stanford researchers launched Stanford Screenomics, an open-source Android platform that allows health researchers to collect screenome data at scale while preserving privacy. The platform can collect over 20 different data types simultaneously through a drag-and-drop interface, including screenshots, GPS location, app usage, and step counts, with HIPAA-compliant storage and multiple privacy protections. Early research has already shown how smartphone usage patterns correlate with mental health fluctuations and can predict mental health crises. This democratizes digital health research by removing technical barriers for researchers without software engineering expertise.

news.stanford.edu

Healthcare7mo ago

CancerIQ — AI platform for earlier cancer detection

CancerIQ, co-founded by Dr. Olufunmilayo Olopade and Feyi Olopade Ayodele, is a health tech company using AI to detect cancer earlier. The company has secured $14M in funding and achieved record screenings in 2025 alongside new partnerships. This represents a direct application of AI to improve cancer detection accuracy and patient outcomes at scale.

x.com

Healthcare7mo ago

Stanford and ETH Zurich — advancing clinically-ready magnetic microrobots for surgery

Stanford's milli-spinner and ETH Zurich's microrobot systems represent clinically ready platforms for steering magnetic microrobots using standard fluoroscopy and X-ray imaging to target blood clots in vessels where conventional thrombectomy fails in 10-30% of cases. The systems are being developed to navigate areas inaccessible to catheters, addressing a significant clinical gap in stroke and thrombotic interventions. This represents a major shift toward untethered robotic systems in minimally invasive surgery, pending resolution of regulatory frameworks for tracking, retrieval, and liability.

x.com

Healthcare7mo ago

FDA approves 1,300+ AI-enabled medical devices; radiology dominant

The FDA's regulatory list now includes over 1,300 AI-enabled medical devices, with radiology comprising the largest share, signaling accelerated clinical adoption of AI in imaging. Real-world screening trials demonstrate AI can reduce mammography reading workload by 44% while maintaining cancer detection rates, and the UK has launched an AI breast-screening trial across 700,000 women. This marks a critical shift in diagnostic capacity and access, particularly for regions facing radiologist shortages, raising urgent questions about clinical risk ownership and integration infrastructure as AI triages scans at population scale.

x.com

Healthcare7mo ago

India launches AI-Enabled E-ICU in Ghaziabad

India's Union Health Minister Shri Jagat Prakash Nadda oversaw the launch of an AI-Enabled E-ICU in Ghaziabad on February 24, 2026, highlighting artificial intelligence's role in critical care settings. The initiative is framed as strengthening healthcare systems by reducing fatalities and enabling faster medical response. This deployment represents a concrete step toward AI-augmented intensive care infrastructure in India's public healthcare system.

x.com

Healthcare7mo ago

Yashoda Medicity — launches AI-Enabled E-ICU Command Centre

Yashoda Medicity launched an AI-Enabled E-ICU Command Centre in Ghaziabad, UP on February 24, 2026, with Union Health Minister JP Nadda emphasizing the government's push to digitize healthcare services under PM Modi's leadership. The facility represents a concrete deployment of AI technology in critical care infrastructure within India's public health ecosystem. This signals accelerating adoption of AI-driven remote intensive care monitoring in emerging healthcare markets.

x.com

Healthcare8mo ago

Sift Biosciences — raises $3.7M Pre-Seed for AI-powered peptide immunotherapy

Sift Biosciences raised $3.7M in Pre-Seed funding from FreeFlow Zone and Lifespan Vision Ventures to build an AI-powered peptide immunotherapy platform. The company is targeting immunologically cold tumors by activating memory T cells through metagenomics and immune profiling. This represents early-stage development of AI-driven cancer immunotherapy, potentially expanding treatment options for previously difficult-to-treat tumor types.

x.com

Healthcare8mo ago

Gates Foundation — launches EVAH Initiative for AI clinical decision support

The Gates Foundation launched the EVAH Initiative in association with Novo Nordisk and Wellcome Trust, focusing on AI-enabled clinical decision support tools. The initiative represents a collaboration between major philanthropic and pharmaceutical organizations to advance AI applications in clinical settings. This signals growing institutional investment in AI tools that could standardize and improve clinical decision-making processes across healthcare systems.

x.com

Healthcare8mo ago

ARPA-H — highlights ENGINE and HYPERDRIVE AI projects

ARPA-H highlighted two AI projects: ENGINE, which uses AI to scale gene therapy manufacturing, and HYPERDRIVE, which develops next-gen AI processors to accelerate biomedical discovery. These projects are positioned as driving the future of health through AI applications. This demonstrates government investment in AI-powered healthcare infrastructure that could transform both therapeutic manufacturing and research capabilities.

x.com